Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Garetosmab - Regeneron Pharmaceuticals

Next Previous
Drug Profile

Garetosmab - Regeneron Pharmaceuticals

Alternative Names: REGN-2477

Latest Information Update: 11 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Regeneron Pharmaceuticals
  • Class Antibodies; Monoclonal antibodies; Obesity therapies; Osteoporosis therapies
  • Mechanism of Action Activin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fibrodysplasia ossificans progressiva
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Fibrodysplasia ossificans progressiva
  • Phase II Obesity
  • Preclinical Osteoporosis
  • No development reported Musculoskeletal disorders

Most Recent Events

  • 02 Jun 2025 Efficacy and adverse events data from phase II COURAGE trials in obesity released by Regeneron Pharmaceuticals
  • 14 May 2025 Regeneron Pharmaceuticals plans a phase I trial for Obesity in May 2025 (Parenteral) (NCT06970405)
  • 13 Mar 2024 Phase-II clinical trials in Obesity (Combination therapy) in USA (IV) (NCT06299098)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top